Concord Biotech Quarterly Results for Trading Insights
In Sept 2025, Concord Biotech (CONCORDBIO) reported revenue ₹263 Cr and net profit ₹63 Cr — revenue -17.8% YoY. Also explore CONCORDBIO price trends to track price trends across different timeframes.
CONCORDBIO Quarterly Results — Revenue, Profit & EPS Highlights
Concord Biotech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with CONCORDBIO fundamental valuation to assess whether the stock is under or overvalued.
- Revenue of ₹263 Cr in Sept 2025 (-40.1% vs Mar 2025, -17.8% vs Sept 2024)
- Net Profit of ₹63 Cr in Sept 2025 (-55.0% vs Mar 2025, -34.4% vs Sept 2024)
- EBITDA of ₹104 Cr in Sept 2025 (-47.5% vs Mar 2025)
- Operating Margin of 36.0% in Sept 2025 (-8.0pp vs Mar 2025)
- Earnings Per Share of ₹6.03 in Sept 2025 (-55.1% vs Mar 2025)
Concord Biotech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CONCORDBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 263 | 439 | 219 | 288 | 320 | -40.1% | -17.8% |
| Net Profit (₹ Cr) | 63 | 140 | 44 | 64 | 96 | - | - |
| EBITDA (₹ Cr) | 104 | 198 | 77 | 105 | 144 | - | - |
| EPS (₹) | 6.03 | 13.42 | 4.21 | 6.08 | 9.15 | - | - |
| Operating Margin (%) | 36.0% | 44.0% | 30.0% | 34.0% | 43.0% | - | - |
CONCORDBIO Share Price Trend — 1-Year Movement Across Quarterly Results
Concord Biotech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Concord Biotech share price chart.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CONCORDBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Concord Biotech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹415,924.72 Cr | 1808.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 139.1 |
|
Divis Laboratories
Sept 2025 |
₹171,625.44 Cr | 6502.5 | 2,860 | 689 | +7.1% | - | 24.1% | 250.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹142,059.09 Cr | 4185.1 | 3,219 | 591 | +11.3% | - | 18.4% | 238.6 |
|
Dr Reddys Laborator…
Sept 2025 |
₹110,348.15 Cr | 1322.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 81.8 |
|
Cipla
Sept 2025 |
₹105,996.98 Cr | 1309.6 | 7,716 | 1,353 | +12.0% | - | 17.5% | 78.3 |
All amounts in ₹ Crores